AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge
New York — November 25, 2025 — Axsome Therapeutics (NASDAQ: AXSM) heads into Tuesday’s session trading just below fresh record highs, powered by blockbuster growth from its depression drug Auvelity, the launch of migraine pill Symbravo, and a rapidly expanding neuroscience pipeline. Shares closed on Monday, November 24, at $151.20, up 1.2% on the day and modestly higher in after-hours trading around $152. That puts AXSM near the top of its 52‑week range of $75.56 to $151.39, valuing the CNS-focused biotech at roughly $7.6 billion. StockAnalysis+1 Over the past year, Axsome’s stock has climbed more than 50% (around 54% on